BUTITTA CYNTHIA M 4

What Happened

• Cynthia Butitta, a director of Olema Pharmaceuticals (OLMA), was granted a derivative award covering 29,500 shares on June 18, 2026. The Form 4 reports the acquisition price as $0.00 (derivative award). This was a grant/award (not an open-market purchase or sale).

Key Details

• Transaction date: 2026-06-18; Form 4 filed: 2026-06-23 (filed one business day late).
• Reported consideration: $0.00 per share (derivative award for 29,500 shares).
• Shares owned after the transaction: not specified in this filing.
• Notable footnote: the shares are subject to an option that vests in 12 equal monthly installments beginning June 18, 2026; if not fully vested earlier, the shares vest in full at the issuer’s next annual meeting of stockholders, subject to continuous service through each vesting date.
• Filing status: late filing — filed one business day after the Form 4 two-business-day deadline.

Context

• This was a compensation grant (an option/derivative award) to a director, not an open-market purchase or a sale. The award vests over time per the footnote; there was no immediate sale of shares reported. Such grants are common for board compensation and reflect issuance of future equity rather than an immediate insider purchase or liquidity event.